http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry
( Ajit Sood ),( Kirandeep Kaur ),( Ramit Mahajan ),( Vandana Midha ),( Arshdeep Singh ),( Sarit Sharma ),( Amarender Singh Puri ),( Bhabhadev Goswami ),( Devendra Desai ),( C. Ganesh Pai ),( Kiran Ped 대한장연구학회 2021 Intestinal Research Vol.19 No.2
Background/Aims: The national registry for inflammatory bowel disease (IBD) was designed to study epidemiology and prescribing pattern of treatment of IBD in India. Methods: A multicenter, cross-sectional, prospective registry was established across four geographical zones of India. Adult patients with ulcerative colitis (UC) or Crohn’s disease (CD) were enrolled between January 2014 and December 2015. Information related to demographics; disease features; complications; and treatment history were collected and analyzed. Results: A total of 3,863 patients (mean age, 36.7±13.6 years; 3,232 UC [83.7%] and 631 CD [16.3%]) were enrolled. The majority of patients with UC (n=1,870, 57.9%) were from north, CD was more common in south (n=348, 55.5%). The UC:CD ratio was 5.1:1. There was a male predominance (male:female=1.6:1). The commonest presentation of UC was moderately severe (n=1,939, 60%) and E2 disease (n=1,895, 58.6%). Patients with CD most commonly presented with ileocolonic (n=229, 36.3%) inflammatory (n=504, 79.9%) disease. Extraintestinal manifestations were recorded among 13% and 20% of patients in UC and CD respectively. Less than 1% patients from both cohorts developed colon cancer (n=26, 0.7%). The commonly used drugs were 5-aminosalicylates (99%) in both UC and CD followed by azathioprine (34.4%). Biologics were used in only 1.5% of patients; more commonly for UC in north and CD in south. Conclusions: The national IBD registry brings out diversities in the 4 geographical zones of India. This will help in aiding research on IBD and improving quality of patient care. (Intest Res 2021;19:206-216)
Analysis of Cyp2b1 gene expression in the rat liver and brain by multiplex PCR
America Vanoye-Carlo,Gabriel Gutiérrez-Ospina,Jaime Marcial-Quino,Saúl Gómez-Manzo,Itzhel Garcia-Torres,Ignacio De la Mora-De la Mora,Sergio Enríquez-Flores,Sara T. Méndez,Bryan V. Phillips-Farfán,Ped 대한독성 유전단백체 학회 2015 Molecular & cellular toxicology Vol.11 No.4
The CYP2B6 enzyme is involved in the metabolism of environmental toxins and endogenous compounds. The expression and activity of the cyp2b6 gene is important for the brain’s ability to detoxify harmful compounds. In rats, the Cyp2b1 gene is homologous to the human Cyp2b6 gene and has an isoform, Cyp2b2, with nearly the same sequence. Although the distinction between them is fundamental, most studies report global changes in CYP2B enzymes due to the complexity of the techniques to detect both genes separately. We instrumented a semi-quantitative technique combining multiplex end point RT-PCR with restriction enzyme assays, allowing us to establish a relatively simple, reproducible and affordable method to distinguish Cyp2b1 gene expression from Cyp2b2. Using this technique, we showed differential Cyp2b1 expression after phenobarbital and ethanol induction in the brain and liver and detected increased Cyp2b1 expression after ethanol treatment in the brain striatum that had not been detected before.